Query Molecule Profile Results
Molecule: 1
Click HERE to jump to Bioactive Database HitsClick HERE to jump to Toxicity Database Hits
Click HERE to jump to Available Compound Database Hits
Click HERE to jump to the ADME Profile
Bioactive Database Search Results
| Bioactive | TanSim | Source | ActClass | Action | LitRef | Annotations |
 |
1.000 | CBNK2005 | bioactive | Known Drug - Indications/Usage: Antiinfective (1) |
NA | CBNKID: 892 MOLNAME: acriflavinium SOLUBILITY: DMSO CAS: 8063-24-9 VENDOR: MicroSource 1500618 NINDS 1500618 |
 |
1.000 | CMCR2004 | Antiseptic | Antiseptic | (1) A. Albert, 'The Acridines', St. Martins Press, NY, 2nd ed., 1966. | ChemicalName: ACRIFLAVINIUM CHLORIDE LogP: -0.49 CommericalSource: Corina 2.62 pKa: NA CAS: 8048-52-0 |
 |
1.000 | MCSR2004 | Anti-Cancer/Antiproliferative | Anti-infective; intercalating agent: interferes with DNA transcription and replication | NULL | MOLNAME: ACRIFLAVINIUM HYDROCHLORIDE SN: 9 ID: 01500618 |
 |
1.000 | MCSR2004 | Bioactive Standard | Therap cat: Anti-infective; intercalating agent: interferes with DNA transcription and replication | NULL | MOLNAME: ACRIFLAVINIUM HYDROCHLORIDE SN: 538985286 ID: 01500618 |
 |
1.000 | MCSR2004 | Cytotoxic agent | intercalating agent: interferes with DNA transcription and replication | NULL | MOLNAME: ACRIFLAVINIUM HYDROCHLORIDE SN: 1210818 ID: 01500618 |
 |
1.000 | MCSRBASC | Bioactive | antiinfective, intercalating agent | NULL | MOLNAME: ACRIFLAVINIUM HYDROCHLORIDE ID: 01500618 |
 |
1.000 | MCSRBASC | Bioactive | antiinfective, intercalating agent | NULL | MOLNAME: ACRIFLAVINIUM HYDROCHLORIDE ID: 01500618 |
 |
1.000 | MDDR2004 | Antiviral (AIDS) | NULL | NULL | ChemicalName: 163882 TestingPhase: Biological Testing CommericalSource: INSERM PatentNumber: NA CAS: NA |
 |
1.000 | MDDR2004 | Antiviral (AIDS) | ACTION - Antiviral agent with antiretroviral activity, | Mathe, G. et al. 9th Int Symp Fut Trends Chemother (March 26-28, Geneva) 1990, 2 . | ChemicalName: ACRIFLAVINE TestingPhase: Phase I CommericalSource: Debiopharm INSERM PatentNumber: NA CAS: 8048-52-0 |
Toxicity Database Search Results
| ToxicMol | TanSim | Source | ActClass | Action | LitRef | Annotations |
 |
1.000 | NCIC2004 | Sub-micromolar growth inbihition activity on 9 NCI Panel(s) No cytotoxic activity on 9 NCI Panels Sub-micromolar cytostatic activity on 1 NCI Panel(s) |
Non-Small Cell Lung_GI_Mean: 6.56 (0.25,9) Colon_GI_Mean: 6.63 (0.26,7) Breast_GI_Mean: 6.25 (0.12,8) Ovarian_GI_Mean: 6.28 (0.33,6) Leukemia_GI_Mean: 6.62 (0.11,6) Renal_GI_Mean: 6.46 (0.34,8) Melanoma_GI_Mean: 6.22 (0.29,8) Prostate_GI_Mean: 6.36 (0.12,2) Central Nervous System_GI_Mean: 6.34 (0.16,6) Leukemia_TG_Mean: 6.02 (0.19,4) |
NA | MOLNAME: 689003 |
Available Compounds Database Search
| Available | SimTan | Source | Category | SuppID | PlateID | Well | Annotations |
 |
1.000 | BASC | ScreenEntirePlates | AB-00130652:BATCH-02 | 01845MS | D03 | COMPANY: Bay Area Screening Center INFO: Microsource 96 well plate |
 |
1.000 | BASC | ScreenEntirePlates | AB-00130652:BATCH-01 | 01829MS | G07 | COMPANY: Bay Area Screening Center INFO: Microsource 96 well plate |
 |
1.000 | MCSR | CherryPickable | 01500618 | NA | NA | COMPANY: Microsource MOLNAME: ACRIFLAVINIUM HYDROCHLORIDE SN: 538985286 |
 |
1.000 | SGSA | CherryPickable | R580422 | NA | NA | COMPANY: Sigma SALOR COLLECTION: Screening Set MW: 224.29 PURITY: 95 SHIPWIN: 7 |
 |
1.000 | TCRS | CherryPickable | ST011984 | NA | NA | COMPANY: Tocris COLLECTION: Screening Set MW: 224.29 PURITY: 90 SHIPWIN: 10 |
ADME Profiler (v1.5) Results
| Probe | ID | ADME Score Reflects the weighted contribution of all the ADME models except BBB; a molecule with a low score is more likely to be orally bioavailable and less toxic | Lip. Viols. | REOS Flags | Int. Perm. Intestinal Permeability Model | ADMET Aq. Sol. | TETKO Aq. Sol. | BBB Model Blood Brain Barrier Penetration Model | Plasma Protein Binding | CYP 2D6 Inh. | Hep Tox | Oprea Viols. | Ghose Viols. | S.F. Flags Suspect Feature Flag |
 |
1 | 2.8 | NONE | NONE |
Good Passive Int. Perm. |
Moderate Solubility:(LogSw =-3.18 mol/L) |
Low Solubility:(LogSw =-4.33 mol/L) |
Moderate BBB Penetration: (LogBBB =-0.47) |
Moderate Plasma Protein Binding (>=90%) |
Likely CYP2D6 Inh: (P=0.73) |
Likely Hep. Toxin: (P=0.97) |
Failed Oprea RBs (Count = 0)Failed 1 of 4 Rules |
Outside Ghose Optimal # Atoms (Count = 17)Failed 1 of 4 Rules |
Aniline_like1 SF Flag(s) |
ADME Model Information
- Lipinski Violations: (1) MW > 500, (2) Num_H_Accs > 10, (3) Num_H_Donors > 5, (4) AlogP > 6; (ref: Lipinski et al, Advanced Drug Delivery Reviews 46, 2001, 3–26)
- REOS Features: Structures deemed inappropriate for HTS; (ref: Rishton, Drug Discovery Today, 2, 9, Sept 1997; M. Hann et al. J. Chem. Inf. Comput. Sci. 39, 1999, 897–902.; Walters et al, Advanced Drug Delivery Reviews 54, 2002, 255–271; consultations with Medicinal Chemists)
- Intestinal Permeability Model (%Abs): (a) 0 = Very Low Absorption; (b) 1 = Low Absorption; (c) 2 = Moderately absorbed; (d) 3 = Well absorbed (>90%); (ref: Egan et al, J. Med. Chem. 2000,43, 3867–3877; Egan, W.J., Lauri, G., Adv. Drug Del. Rev., 54, 273, 2001)
- ADMET Solubility Model (Log mol/L): (a) 0 = Extremely Low Solubility (<-8.0); (b) 1 = Very Low Solubility (-8.0 – -6.0); (c) 2 = Low Solubility (-6.0 – -4.0); (d) 3 = Moderate Solubility (-4.0 – -2.0); (e) 4 = Optimal Solubility (-2.0 – 0.0); (f) 5 = Very Soluble (>0.0); (g) 6 = Undefined; (ref: Cheng, A. and Merz, Jr., K. "Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships," J. Med. Chem. 2003, 46, 3572–3580).
- TETKO Solubility Model (Log mol/L): (a) 0 = Extremely Low Solubility (<-8.0); (b) 1 = Very Low Solubility (-8.0 – -6.0); (c) 2 = Low Solubility (-6.0 – -4.0); (d) 3 = Moderate Solubility (-4.0 – -2.0), (e) 4 = Optimal Solubility (-2.0 – 0.0); (f) 5 = Very Soluble (>0.0); (ref: Scitegic's Pipeline Pilot model based on Tetko et al.,J Chem Inf. Comput. Sci, 2001, 41, 1488–1493, "Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices)
- Blood Brain Barrier (BBB) Permation: (a) 0 = Undefined; (b) 1 = Outside Confidence Range; (c) 2 = Low Permation (Blood:Brain > 0.3); (d) 3 = Medium Permation (Blood:Brain 0.3 > 1:1); (e) 4 = High Permeation Brain:Blood 1:1 > 5:1); (f) 5 = Very High Permation (Blood:Brain > 5:1); (ref: Accelrys Proprietary model);
- Plasma Protein Binding (PPB): (a) 0 = <90%; (b) 1 = >=90%, (c) 2 = >95%; (ref: Dixon, S.L. and Merz, K.M.M., Jr. "One-Dimensional Molecular Representations and Similarity Calculations: Methodology and Validation," J. Med. Chem., 2001, 44, 3795–3809.)
- CYP 2D6 Inhibition: (a) 0 = Non-Inhibitor; (b) 1 = Inhibitor; (ref: Dixon, S.L., Villar, H.O., J. Comput. Aided Mol. Design, 13, 533 (1999).; Susnow, R.G., Dixon, SL, "Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition," J. Chem. Inf. Comput. Sci., 2003, 43, 1308–1315)
- Hepatotoxicity: (a) 0 = Not Toxic; (b) 1 = Toxic; (ref: Dixon, SL; Villar, H.O., J. Comput. Aided Mol. Design, 13, 533 (1999); Cheng, A. and Dixon, SL In silico models for the prediction of dose-dependent human hepatotoxicity, J. Comput. Aided Mol. Design, 17, 811–823. (2003));
- Ghose Violations: (1) -0.4 <= AlogP <= 5.6, (2) 160 <= MW <= 480, (3) 40 <= MR <= 130, (4) 20 <= Num_Atoms <= 70; (ref: A.K. Ghose et al, J. Comb. Chem. 1, 1999, 55–67)
- Oprea Violations: (1) Num_H_Donors > 2, (2) 2 <= Num_H_Accs <= 9, (3) 2 <= Num_RBs <= 8, (4) 1 <= Num_Rings <= 4; (ref: Oprea, Journal of Computer-Aided Molecular Design, 14: 251–264, 2000)
- Suspect Substructure Violations: Compounds gleamed from medicinal chemistry literature that are known to be problematic for developing drug candidates